CSIMarket
 


Alx Oncology Holdings Inc  (ALXO)
Other Ticker:  
 
 

ALXO's Income from Cont. Operations Growth by Quarter and Year

Alx Oncology Holdings Inc's Income from Cont. Operations results by quarter and year




ALXO Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -30.71 -28.44 21.51
III Quarter September -50.99 -35.32 -24.57 -10.18
II Quarter June -34.16 -32.92 -16.27 -11.33
I Quarter March -30.18 -24.53 -14.19 0.00
FY   -115.33 -123.48 -83.47 0.00



ALXO Income from Cont. Operations third quarter 2023 Y/Y Growth Comment
Alx Oncology Holdings Inc in the third quarter 2023 recorded loss from continued operations of $ -50.99 millions.

According to the results reported in the third quarter 2023, Alx Oncology Holdings Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Alx Oncology Holdings Inc' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2023.




ALXO Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Alx Oncology Holdings Inc's third quarter 2023 Income from Cont. Operations $ -50.99 millions ALXO's Income Statement
Alx Oncology Holdings Inc's third quarter 2022 Income from Cont. Operations $ -35.32 millions Quarterly ALXO's Income Statement
New: More ALXO's historic Income from Cont. Operations Growth >>


ALXO Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Alx Oncology Holdings Inc's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ALXO's III. Quarter Q/Q Income from Cont. Operations Comment
Current loss from continued operations of -50.99 millions by Alx Oncology Holdings Inc appear even less good considering the loss from continued operations -34.16 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Alx Oncology Holdings Inc achieved highest sequential Income from Cont. Operations growth. While Alx Oncology Holdings Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ALXO's III. Quarter Q/Q Income from Cont. Operations Comment
Recent loss from continued operations of -50.99 millions by Alx Oncology Holdings Inc come out even worse if you take a look at loss from continued operations -34.16 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Alx Oncology Holdings Inc achieved highest sequential Income from Cont. Operations growth. While Alx Oncology Holdings Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Alx Oncology Holdings Inc's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -146.04 $ -130.37 $ -129.13 $ -123.48 $ -121.21
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Alx Oncology Holdings Inc' has realized cumulative trailing twelve months loss from continued operations of $ -146 millions in the Sep 30 2023 period.
The results are worsening as the cumulative loss from continued operations is inflating from $ -130.37 millions for the period from Jun 30 2023 to Sep 30 2022 and $ -110.457 millions for the twelve months ending in the quarter a year ago.

Alx Oncology Holdings Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Alx Oncology Holdings Inc' has realized cumulative trailing twelve months loss from continued operations of $ -146 millions in the Sep 30 2023 period.
The situation is getting worse as the cumulative loss from continued operations is becoming larger from $ -130.37 millions in the twelve months ending a quarter before and $ -110.457 millions for the twelve months ending in the quarter a year ago Eliza  N. Wright mentioned.

Alx Oncology Holdings Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
ALXO's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for ALXO's Competitors
Income from Cont. Operations Growth for Alx Oncology Holdings Inc's Suppliers
Income from Cont. Operations Growth for ALXO's Customers

You may also want to know
ALXO's Annual Growth Rates ALXO's Profitability Ratios ALXO's Asset Turnover Ratio ALXO's Dividend Growth
ALXO's Roe ALXO's Valuation Ratios ALXO's Financial Strength Ratios ALXO's Dividend Payout Ratio
ALXO's Roa ALXO's Inventory Turnover Ratio ALXO's Growth Rates ALXO's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2023
Integer Holdings Corporation69.75%$ 69.752 millions
Merit Medical Systems Inc69.16%$ 69.159 millions
Align Technology inc 67.02%$ 67.025 millions
Select Medical Holdings Corp59.51%$ 59.513 millions
Infusystem Holdings Inc55.53%$ 55.530 millions
Incyte Corporation51.87%$ 51.868 millions
Teva Pharmaceutical Industries Limited51.72%$ 51.724 millions
Semler Scientific Inc 50.04%$ 50.041 millions
Iradimed Corporation47.86%$ 47.856 millions
Merck and Co Inc 46.02%$ 46.019 millions
Lftd Partners Inc 45.85%$ 45.849 millions
Msa Safety Incorporated45.32%$ 45.317 millions
Option Care Health Inc 45.02%$ 45.022 millions
Ir med Inc 37.73%$ 37.734 millions
Lemaitre Vascular Inc 37.50%$ 37.500 millions
Becton Dickinson And Company36.61%$ 36.607 millions
Encompass Health Corporation34.15%$ 34.152 millions
West Pharmaceutical Services Inc 33.75%$ 33.748 millions
Addus Homecare Corporation33.51%$ 33.509 millions
Halozyme Therapeutics Inc 32.78%$ 32.779 millions
Chemed Corporation31.80%$ 31.799 millions
Intuitive Surgical Inc 29.29%$ 29.289 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com